Yesterday afternoon, the National Health Commission held a press conference to introduce the situation of further strengthening the medical treatment of severe pneumonia patients infected with new coronavirus. The reporter learned from the meeting that as of February 3, the case fatality rate of confirmed cases of new coronavirus infection pneumonia in the country was 2.1%. The majority of deaths were males, and over 80% were elderly people over 60 years old.

        As of yesterday, a total of 220,865 person-times of medical consultations were issued by medical institutions nationwide, a decrease of 16710 person-times from the previous day, a decrease of 7%. There were 10,342 new cases of watching, and at 24 o'clock that day, there were still 32,545 people watching. Among them, Wuhan City received 12568 person-times of hot clinics throughout the day, and 194 cases were newly watched.

        Sun Yanrong, deputy director of the Biological Center of the Ministry of Science and Technology, introduced at the meeting that since the outbreak, the Ministry of Science and Technology has formed a scientific research team with 12 departments and units including the National Health and Health Commission and the Development and Reform Commission. A team of scientific research experts composed of experts has launched a total of 16 emergency research projects, focusing on several research directions such as virus tracing, drug research and development, vaccine research and development, testing reagents and experimental animal models.

        In terms of drug research, some drugs with potential anti-new coronavirus effects have been preliminarily selected, and the efficacy verification is being stepped up. In vaccine research, multiple technologies are being promoted in parallel to increase the success rate.

        Among them, a batch of marketed drugs with antiviral activity among chloroquine phosphate, fapiravir, and proprietary Chinese medicines were found during the promotion of drug research and development.

        Sun Yanrong introduced that chloroquine phosphate is an antimalarial drug already on the market, and has shown good anti-coronavirus activity in in vitro studies. "At present, we are stepping up the advancement of animal experiments and clinical trials."

        Redoxir is a drug that has been used to treat Ebola virus infection abroad, and has not yet completed all clinical trials abroad. And it showed good in vitro activity during virus screening in relevant domestic research institutes. A few days ago, the State Food and Drug Administration has notified applicants-China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences to conduct clinical trials.

        Yesterday afternoon, the National Health Commission held a press conference to introduce the situation of further strengthening the medical treatment of severe pneumonia patients infected with new coronavirus. The reporter learned from the meeting that as of February 3, the case fatality rate of confirmed cases of new coronavirus infection pneumonia in the country was 2.1%. The majority of deaths were males, and over 80% were elderly people over 60 years old.

        As of yesterday, a total of 220,865 person-times of medical consultations were issued by medical institutions nationwide, a decrease of 16710 person-times from the previous day, a decrease of 7%. There were 10,342 new cases of watching, and at 24 o'clock that day, there were still 32,545 people watching. Among them, Wuhan City received 12568 person-times of hot clinics throughout the day, and 194 cases were newly watched.

        Sun Yanrong, deputy director of the Biological Center of the Ministry of Science and Technology, introduced at the meeting that since the outbreak, the Ministry of Science and Technology has formed a scientific research team with 12 departments and units including the National Health and Health Commission and the Development and Reform Commission. A team of scientific research experts composed of experts has launched a total of 16 emergency research projects, focusing on several research directions such as virus tracing, drug research and development, vaccine research and development, testing reagents and experimental animal models.

        In terms of drug research, some drugs with potential anti-new coronavirus effects have been preliminarily selected, and the efficacy verification is being stepped up. In vaccine research, multiple technologies are being promoted in parallel to increase the success rate.

        Among them, a batch of marketed drugs with antiviral activity among chloroquine phosphate, fapiravir, and proprietary Chinese medicines were found during the promotion of drug research and development.

        Sun Yanrong introduced that chloroquine phosphate is an antimalarial drug already on the market, and has shown good anti-coronavirus activity in in vitro studies. "At present, we are stepping up the advancement of animal experiments and clinical trials."

        Redoxir is a drug that has been used to treat Ebola virus infection abroad, and has not yet completed all clinical trials abroad. And it showed good in vitro activity during virus screening in relevant domestic research institutes. A few days ago, the State Food and Drug Administration has notified applicants-China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences to conduct clinical trials.